United States
Print page content Print
Increase text size Decrease text size
Text Size

VANGUARD® CIV H3N8

Vaccine provides an aid in control of disease associated with canine influenza virus H3N8

VANGUARD CIV

The Vanguard CIV H3N8 vaccine is part of the Zoetis family of CIRD vaccines. Vanguard CIV H3N8 vaccine is licensed for use in healthy dogs 8 weeks of age or older. It is recommended for dogs housed in communal facilities or that are in contact with other dogs in locations such as:

  •  Veterinary clinics
  •  Dog daycare and parks
  •  Grooming facilities and kennels
  •  Dog events
Expand All
    • A killed whole virus vaccine (CIV H3N8)
    • Efficacy demonstrated using a heterologous challenge model
    • Reduces clinical signs of canine influenza1
    • Significant reduction in CIV shedding (P<0.0001)1
    • Significant reduction in lung consolidation (P<0.0238)1
    • Low incidence of adverse events following vaccination2
    • Thimerosal free
    • Covered by the Companion Animal Immunization Support Guarantee
  • Directions: Vaccination of healthy dogs is recommended. Shake well. Aseptically administer 1 mL subcutaneously. Healthy dogs 8 weeks of age and older should receive 2 doses administered 3 weeks apart. Annual revaccination with a single dose is recommended.

  • 1. Data on file, Study Report No. 3161R-60-09-383, Zoetis LLC.
    2. Data on file, Study Report No. 3467R-60-06-291, Zoetis LLC.

     


Precautions: Store at 2°-7°C (35°-45°F). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Contains gentamicin as preservative.

Technical inquiries should be directed to Zoetis Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only.

SAB-00520